Addressing Uncertainties Associated Medication Approved Through Accelerated Approval Pathway
March 28th 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses how healthcare providers and patients navigate the potential benefits and uncertainties associated with a medication approved through the accelerated approval pathway.
Petros Pharmaceuticals Executive Discusses Wider Availability of Oral Contraceptive
March 28th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Fady Boctor, President, Chief Commercial Officer, Petros Pharmaceuticals talks about the recent availability of Opill as an over-the-counter (OTC) contraceptive.
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
March 27th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical research.
Do Mixed Results Impact Potential Real-World Effectiveness and Potential Market Adoption?
March 26th 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, explore mixed trial results impact the confidence in their potential real-world effectiveness and potential market adoption.
UCB's Women of Childbearing Age Program
March 25th 2024In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, talks about the program's creation and their most successful strategies for encouraging the inclusion of women of childbearing age in clinical trials.
Addressing Unmet Needs in Schizophrenia, Pulmonary Arterial Hypertension & NASH
March 22nd 2024In this Pharmaceutical Executive video interview, Optum Rx clinical pharmacist, Arash Sadeghi, discusses the three drugs featured in their Drug Pipeline Insights Report for 2024 and which unmet needs they address.
Combining Cutting-Edge Technologies with Traditional Marketing
March 20th 2024In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, talks about how he has successfully combined cutting-edge technologies with traditional marketing approaches in his past ventures.
Utilizing Generative AI for Rapid Content Creation and Distribution
March 19th 2024In this Pharmaceutical Executive video interview, Kaveh Vahdat, Founder and President of RiseOpp, explains utilizing generative AI for rapid content creation and how AI-driven automation of that content distribution has increased visibility.
Hurdles Hindering the Translation of AI-Powered Research into Tangible Clinical Benefits
March 15th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses why no novel active substances have yet been brought to market through AI technology despite increasing investments in the space for drug discovery as shown in IQVIA's Global Trends in R&D 2024 report.
Benefits and Limitations of Strategies Used to Improve Clinical Development Productivity
March 13th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report including the potential benefits and limitations of novel trial designs and decentralized methodologies.
Putting Menopause Medication on the Main Stage
March 12th 2024In this Pharmaceutical Executive interview, Jill Jaroch, Senior Director, Women’s Health & Urology Marketing at Astellas, discusses the decision to continue VEOZAH's presence during the big game, the inspiration and message behind the commercial, and if Taylor Swift played a factor in their decision making
Contributing Factors to the Growing Gap in Access Between the US and Europe
March 11th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report that shows why the US continued to lead in new drug launches in 2023.
Behind the Push and Pull of Copay Accumulator Programs
March 11th 2024In this Pharmaceutical Executive video interview, Chris Dowd, senior vice president of market development, ConnectiveRx, discusses the evolution of drug copay adjustment programs and the circumstances that fueled their controversy across industry, political, and healthcare community circles.
How Data Integrity Landscape Will Evolve Over the Five Years
March 8th 2024In this Pharmaceutical Executive video interview, Daniel Ayala, Chief Security and Trust Officer, Dotmatics discusses how the data integrity landscape will evolve over the next five years and what extent bench scientists in the lab focused on data integrity.
The Biggest Challenges Facing Broader Adoption of Novel Cell and Gene Therapies
March 7th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses the biggest challenges facing the broader adoption of novel cell and gene therapies from IQVIA's Global Trends in R&D 2024 report.
What's Causing the Slowdowns in Trial Starts?
March 5th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report and what specific factors are causing this slowdown in clinical trial starts.
AstraZeneca VP, Head of US Lung Cancer Franchise Discusses the Recent FDA Approval of TAGRISSO
February 27th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Arun Krishna, VP, Head of US Lung Cancer Franchise, AstraZeneca, talks about the FDA's approval of TAGRISSO with the addition of chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
IQVIA Executive Director Discusses Global Use of Medicines 2024 Report - Part 1
February 23rd 2024Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses key findings from their Global Use of Medicines 2024 report as well as the significant projected growth in spending and growth in diabetes and global obesity
Jonathan Miller, General Counsel, US Hemp Roundtable Discusses FDA Regulation of the Hemp Market
February 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Jonathan Miller, General Counsel, US Hemp Roundtable, discusses recent efforts that urge the House Energy and Commerce Committee to expedite an FDA hearing on the hemp market.